Merck (010683053) Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
010683053 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$118.50 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.30 |
| 1 Month Change | 8.52% |
| 3 Month Change | -70.38% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 010683053 | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -1.8% | 2.0% | 0.4% |
| 1Y | n/a | 25.1% | 4.0% |
Return vs Industry: Insufficient data to determine how 010683053 performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 010683053 performed against the Swiss Market.
Price Volatility
| 010683053 volatility | |
|---|---|
| 010683053 Average Weekly Movement | 24.4% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 8.9% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: 010683053's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 010683053's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
Merck & Co., Inc. Fundamentals Summary
| 010683053 fundamental statistics | |
|---|---|
| Market cap | US$296.13b |
| Earnings (TTM) | US$18.25b |
| Revenue (TTM) | US$65.01b |
Is 010683053 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 010683053 income statement (TTM) | |
|---|---|
| Revenue | US$65.01b |
| Cost of Revenue | US$14.90b |
| Gross Profit | US$50.11b |
| Other Expenses | US$31.86b |
| Earnings | US$18.25b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 7.35 |
| Gross Margin | 77.08% |
| Net Profit Margin | 28.08% |
| Debt/Equity Ratio | 79.7% |
How did 010683053 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 07:34 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck & Co., Inc. is covered by 47 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Luisa Hector | Berenberg |